Spots Global Cancer Trial Database for Allogeneic Hematopoietic Stem Cell Transplantation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Allogeneic Hematopoietic Stem Cell Transplantation

Official Title: Feasibility Study on Allogeneic Hematopoietic Stem Cell Transplantation Following Fludarabine-Busulfan-ALS-based Reduced-intensity Conditioning in Children With Hematological Malignancy or Solid Tumor Not Responding to Standard Therapy or for Which the Indication for Allograft is Maintained But Cannot be Carried Out Due to the Toxicity Involved in Myeloablative Conditioning.

Study ID: NCT00750126

Conditions

Solid Tumors

Hematologic Neoplasms

Interventions

Fludarabine, Busulfan, Thymoglobulin

Study Description

Brief Summary: To assess the engraftment of hematopoietic stem cells following reduced-intensity conditioning in children presenting with solid tumors or hematological malignancy by evaluating post-transplantation chimerism and hematological reconstitution. To study acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post-transplantation To study the effectiveness of the protocol on tumor response. To study overall survival.

Detailed Description: Primary criterion * Hematological reconstitution and chimerism post-transplantation Secondary criteria * Adverse effects, graft-related mortality at D90 and at 12 months, incidence and severity of acute and/or chronic GVH reactions * Analysis of variations in post-transplantation immunological function profiles * Median duration of response in therapy-responsive patients and median duration of stability in stabilized patients